Sandu [SANDUPHQ] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Sandu Pharmaceuticals, Inc.

BSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sandu Pharmaceuticals, Inc. wins in 10 metrics, Gujarat Themis Biosyn Ltd. wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Sandu Pharmaceuticals, Inc. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) 20.68 73.73 Sandu Pharmaceuticals, Inc.
Price-to-Book Ratio 1.00 13.36 Sandu Pharmaceuticals, Inc.
Debt-to-Equity Ratio 1.06 27.04 Sandu Pharmaceuticals, Inc.
PEG Ratio 0.27 -17.55 Sandu Pharmaceuticals, Inc.
EV/EBITDA 14.48 52.76 Sandu Pharmaceuticals, Inc.
Profit Margin (TTM) 3.06% 29.99% Gujarat Themis Biosyn Ltd.
Operating Margin (TTM) 4.66% 40.16% Gujarat Themis Biosyn Ltd.
EBITDA Margin (TTM) 4.66% 40.16% Gujarat Themis Biosyn Ltd.
Return on Equity 3.69% 19.64% Gujarat Themis Biosyn Ltd.
Return on Assets (TTM) 2.78% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $104,000 $-251.22M Sandu Pharmaceuticals, Inc.
Dividend Yield 1.61% 0.17% Sandu Pharmaceuticals, Inc.
1-Year Return -19.97% 15.75% Gujarat Themis Biosyn Ltd.
Price-to-Sales Ratio (TTM) 0.63 22.23 Sandu Pharmaceuticals, Inc.
Enterprise Value $388.60M $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 0.58 22.65 Sandu Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 57.96% 83.29% Gujarat Themis Biosyn Ltd.
Revenue per Share (TTM) $69 $15 Sandu Pharmaceuticals, Inc.
Earnings per Share (Diluted) $2.11 $4.40 Gujarat Themis Biosyn Ltd.
Beta (Stock Volatility) 0.07 -0.17 Gujarat Themis Biosyn Ltd.

Sandu Pharmaceuticals, Inc. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

SANDUPHQ
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sandu Pharmaceuticals, Inc.4.57%3.52%13.34%24.67%11.02%14.83%
Gujarat Themis Biosyn Ltd.-0.57%-4.89%4.00%38.98%-1.40%-12.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sandu Pharmaceuticals, Inc.-19.97%-28.02%-9.05%49.41%206.86%307.54%
Gujarat Themis Biosyn Ltd.15.75%76.92%76.92%76.92%76.92%76.92%

Performance & Financial Health Analysis: Sandu Pharmaceuticals, Inc. vs Gujarat Themis Biosyn Ltd.

MetricSANDUPHQGUJTHEM
Market Information
Market Cap i₹421.61M₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i7,69979,452
90 Day Avg. Volume i5,431106,446
Last Close₹43.51₹385.10
52 Week Range₹30.00 - ₹58.28₹225.05 - ₹479.00
% from 52W High-25.34%-19.60%
All-Time High₹86.00 (Apr 25, 2022)₹479.00 (Oct 27, 2025)
% from All-Time High-49.41%-19.60%
Growth Metrics
Quarterly Revenue Growth0.02%0.10%
Quarterly Earnings Growth0.76%-0.04%
Financial Health
Profit Margin (TTM) i0.03%0.30%
Operating Margin (TTM) i0.05%0.40%
Return on Equity (TTM) i0.04%0.20%
Debt to Equity (MRQ) i1.0627.04
Cash & Liquidity
Book Value per Share (MRQ)₹43.50₹24.29
Cash per Share (MRQ)₹3.85₹0.92
Operating Cash Flow (TTM) i₹5.35M₹970.68M
Levered Free Cash Flow (TTM) i₹15.52M₹487.72M
Dividends
Last 12-Month Dividend Yield i1.61%0.17%
Last 12-Month Dividend i₹0.80₹0.67

Valuation & Enterprise Metrics Analysis: Sandu Pharmaceuticals, Inc. vs Gujarat Themis Biosyn Ltd.

MetricSANDUPHQ (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.6873.73
Forward P/E iN/AN/A
PEG Ratio i0.27-17.55
Price to Sales (TTM) i0.6322.23
Price to Book (MRQ) i1.0013.36
Market Capitalization
Market Capitalization i₹421.61M₹35.41B
Enterprise Value i₹388.60M₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i0.5822.65
Enterprise to EBITDA i14.4852.76
Risk & Other Metrics
Beta i0.07-0.17
Book Value per Share (MRQ) i₹43.50₹24.29

Financial Statements Comparison: Sandu Pharmaceuticals, Inc. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSANDUPHQ (2025)GUJTHEM (2025)
Revenue/Sales i671.92M1.51B
Cost of Goods Sold i332.04M318.78M
COGS % of Revenue i49.4%21.1%
Gross Profit i339.88M1.19B
Gross Margin i50.6%78.9%
Research & Development i2.33M34.37M
Operating Income (EBIT) i20.94M642.49M
Operating Margin i3.1%42.6%
EBITDA i29.26M713.04M
EBITDA Margin i4.4%47.3%
Pre-Tax Income i21.59M655.38M
Pre-Tax Income % of Revenue i3.2%43.5%
Income Tax i6.07M167.66M
Income Tax % of Revenue i0.9%11.1%
Net Income (Profit) i15.52M487.72M
Profit Margin i2.3%32.3%

Balance Sheet & Liquidity Metrics

MetricSANDUPHQ (2025)GUJTHEM (2025)
Cash & Equivalents i13.04M116.94M
Total Current Assets i262.99M519.73M
Total Current Assets % of Revenue i39.1%34.5%
Total Current Liabilities i120.86M205.60M
Total Current Liabilities % of Revenue i18.0%13.6%
Long-Term Debt i4.19M296.36M
Long-Term Debt % of Revenue i0.6%19.7%
Total Shareholders Equity i420.17M2.48B
Retained Earnings i95.24M2.37B
Retained Earnings % of Revenue i14.2%157.4%
Property, Plant & Equipment i7.46M411.30M

Cash Flow Statement Comparison

MetricSANDUPHQ (2025)GUJTHEM (2025)
Operating Cash Flow i5.35M970.68M
Operating Cash Flow % of Revenue i0.8%64.4%
Capital Expenditures i-9.38M-1.16B
Free Cash Flow i104,000-251.22M
FCF Margin i0.0%-16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSANDUPHQGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i9.66M108.97M
Float Shares i3.21M29.52M
% Held by Insiders i65.51%71.98%
% Held by Institutions i0.00%1.18%
% Held by Public i34.49%26.84%

Dividend Analysis & Yield Comparison: Sandu Pharmaceuticals, Inc. vs Gujarat Themis Biosyn Ltd.

MetricSANDUPHQGUJTHEM
Last 12-Month Dividend i₹0.80₹0.67
Last 12-Month Dividend Yield i1.61%0.17%
3-Year Avg Annual Dividend i₹1.02₹0.22
3-Year Avg Dividend Yield i1.12%0.17%
3-Year Total Dividends i₹3.05₹0.67
Ex-Dividend DateSep 19, 2024Sep 04, 2025